104 Results for "

RNA+binding

" in MedChemExpress (MCE) Product Catalog:
Products (104)

104 Results for "RNA+binding" in MCE Product Catalog:

4
4 Cited Publications
Cat. No.: HY-108466
CAS No.: 37854-59-4
Purity:  98.63%
Target:  

Apoptosis

Research Areas:  

Neurological Disease Cancer

Ro 08-2750 is a non-peptide and reversible nerve growth factor (NGF) inhibitor which binds to NGF, and with an IC50 of ~ 1 μM. Ro 08-2750 inhibits NGF binding to p75 NTR selectively over TRKA . Ro 08-2750 is a selective MSI RNA-binding activity inhibitor, with an IC50 of 2.7 μM .
2
2 Cited Publications
Cat. No.: HY-B0268
CAS No.: 74011-58-8
Synonyms: AT 2266; CI 919
Enoxacin (AT 2266), a fluoroquinolone, interferes with DNA replication and inhibits bacterial DNA gyrase (IC50=126 µg/ml) and topoisomerase IV (IC50=26.5 µg/ml). Enoxacin is a miRNA processing activator and enhances siRNA-mediated mRNA degradation and promotes the biogenesis of endogenous miRNAs. Enoxacin has potent activities against gram-positive and -negative bacteria. Enoxacin is a cancer-specific growth inhibitor that acts by enhancing TAR RNA-binding protein 2 (TRBP)-mediated microRNA processing .
2
2 Cited Publications
Cat. No.: HY-B0268A
CAS No.: 84294-96-2
Synonyms: Enoxacin sesquihydrate; AT-2266 hydrate; CI-919 hydrate
Enoxacin hydrate (Enoxacin sesquihydrate), a fluoroquinolone, interferes with DNA replication and inhibits bacterial DNA gyrase (IC50=126 µg/ml) and topoisomerase IV (IC50=26.5 µg/ml). Enoxacin hydrate is a miRNA processing activator and enhances siRNA-mediated mRNA degradation and promotes the biogenesis of endogenous miRNAs. Enoxacin hydrate has potent activities against gram-positive and -negative bacteria. Enoxacin hydrate is a cancer-specific growth inhibitor that acts by enhancing TAR RNA-binding protein 2 (TRBP)-mediated microRNA processing .
2
2 Cited Publications
Cat. No.: HY-124828
CAS No.: 958843-91-9
Purity:  98.66%
Target:  

HuR

Research Areas:  

Cancer

CMLD-2, an inhibitor of HuR-ARE interaction, competitively binds HuR protein disrupting its interaction with adenine-uridine rich elements (ARE)-containing mRNAs (Ki=350 nM). CMLD-2 induces apoptosis exhibits antitumor activity in different cancer cells as colon, pancreatic, thyroid and lung cancer cell lines. Hu antigen R (HuR) is an RNA binding protein, can regulate target mRNAs stability and translation .
2
2 Cited Publications
Cat. No.: HY-153918
CAS No.: 2955634-67-8
Purity:  99.50%
Target:  

Androgen Receptor

Research Areas:  

Cancer

(R)-SKBG-1 is a covalent inhibitor targeting the RNA binding protein NONO. (R)-SKBG-1 can reduce the expression of androgen receptor (AR) and its splice variants, inhibiting cancer cell proliferation. (R)-SKBG-1 inhibits androgen receptor expression with IC50 of 3.1 μM and 5.5 μM for AR-FL mRNA and AR-V7 mRNA, respectively. (R)-SKBG-1 interferes with the gene regulatory network of cancer cells and inhibits cancer cell growth by stabilizing the interaction between NONO and mRNA. (R)-SKBG-1 can be used in the study of cancers related to NONO dysfunction, such as prostate cancer .
1
1 Cited Publications
Cat. No.: HY-134601
CAS No.: 1215115-03-9
Purity:  98.91%
Target:  

HuR

Research Areas:  

Cancer

KH-3 is a potent RNA-binding protein Hu antigen R (HuR) inhibitor with an IC50 value of 0.35 μM. KH-3 has anti-proliferative activity. KH-3 suppresses breast cancer cell invasion as well as delays the initiation of lung colonies by disrupting HuR-FOXQ1 mRNA interaction .
1
1 Cited Publications
Cat. No.: HY-30234A
CAS No.: 1163-36-6
Clemizole hydrochloride is an H1 histamine receptor antagonist, is found to substantially inhibit HCV replication. Clemizole hydrochloride is an inhibitor of TRPC5 channel. The IC50 of Clemizole hydrochloride for RNA binding by NS4B is 24 nM, whereas its EC50 for viral replication is 8 μM.
1
1 Cited Publications
Cat. No.: HY-147918
CAS No.: 124811-87-6
Purity:  99.92%
Target:  

DNA/RNA Synthesis

Research Areas:  

Cancer

Anticancer agent 73 (compound CIB-3b) is a anticancer agent, potently targeting TAR RNA-binding protein 2 (TRBP) and disrupts its interaction with Dicer. Anticancer agent 73 can rebalance the expression profile of oncogenic or tumor-suppressive miRNAs. Anticancer agent 73 suppresses the proliferation and metastasis of HCC in vitro and in vivo .
1
1 Cited Publications
Cat. No.: HY-30234
CAS No.: 442-52-4
Clemizole is an H1 histamine receptor antagonist, is found to substantially inhibit HCV replication. Clemizole is an inhibitor of TRPC5 channel. The IC50 of Clemizole for RNA binding by NS4B is 24±1 nM, whereas its EC50 for viral replication is 8 µM.
1
1 Cited Publications
Cat. No.: HY-P72145
Purity:  ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: Cirbp; CirpCold-inducible RNA-binding protein; A18 hnRNP; Glycine-rich RNA-binding protein CIRP
Species:  
Source:  
1
1 Cited Publications
Cat. No.: HY-P76261
Purity:  ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: Cold-inducible RNA-binding protein A; XCIRP; cirbp-a; CIRP-1
Species:  
Source:  
Cat. No.: HY-174228
CAS No.: 552829-57-9
Research Areas:  

Cancer

I3IN-002 is a small-molecule RNA-binding protein IGF2BP3 inhibitor with an IC50 value of approximately 2 μM in SEM cells. I3IN-002 interferes with interaction with m6 A-modified mRNAs, disrupting the stabilization of target genes (such as CDK6, MYC, and BCL2) to inhibit leukemic cell growth, induce cell cycle arrest, and promote apoptosis. I3IN-002 is promising for research of B-cell acute lymphoblastic leukemia .
Cat. No.: HY-21997
CAS No.: 136834-22-5
DMT-2'fluoro-da(bz) amidite is a key intermediate for synthesizing antisense oligonucleotides with high nuclease resistance, high RNA binding affinity, and maintained base-pair specificity .
Cat. No.: HY-P5960
Synonyms: PTBP1 α3-helix derived peptide P6 TFA
Target:  

DNA/RNA Synthesis

Research Areas:  

Cancer

PTBP1-RNA-binding inhibitor (PTBP1 α3-helix derived peptide) P6 TFA is a cell-permeable PTBP1 inhibitor. PTBP1-RNA-binding inhibitor P6 TFA binds to the α3 helix binding site of the PTBP1 RRM1 domain, and disrupts the synergistic RNA-binding effect of the RRM1 and RRM2 domains of PTBP1. PTBP1-RNA-binding inhibitor P6 (TFA) regulates the regulatory pattern of PTBP1-related alternative splicing events, and thus exhibits anticancer potential .
Cat. No.: HY-175238
CAS No.: 1309288-83-2
Research Areas:  

Neurological Disease Cancer

KI-DX-014 is a DDX21 inhibitor with high RNA-binding inhibitory activity (IC50 of 3.31 μM). KI-DX-014 targets DDX21’s intrinsically disordered C-terminal domain, inhibits DDX21-structured RNA interaction, modulates DDX21’s RNA-dependent ATPase activity, and disrupts DDX21 biomolecular condensate formation. KI-DX-014 attenuates in vitro P-TEFb release from the 7SK snRNP complex, suppresses P-TEFb-dependent RNA polymerase II CTD phosphorylation, and induces developmental defects in zebrafish embryos. KI-DX-014 acts as a chemical probe for dissecting DDX21 functions in normal physiology and disease states. KI-DX-014 can be used for cancers and neurodegenerative disorders research .
Cat. No.: HY-176471
CAS No.: 3070282-38-8
Target:  

Insulin Receptor

Research Areas:  

Cancer

IGF2BP3-IN-1 (Compound I3IN-122) is an IGF2BP3 (a RNA binding protein) inhibitor (IC50: > 50 μM), and can be used for cancer research .
Cat. No.: HY-175324
CAS No.: 3098773-64-6
Target:  

Molecular Glues HuR

Research Areas:  

Cancer

MG-HuR2 is a molecular glue degrader targeting the oncogenic RNA-binding protein HuR (IC50=0.5 μM). MG-HuR2 is promising for research of HuR-overexpressing malignancies (e.g., breast cancer) .
Cat. No.: HY-163759
CAS No.: 3040301-46-7
Target:  

Molecular Glues HuR

Research Areas:  

Cancer

HuR degrader 2 (Compound 3) is a molecule glue, which targets RNA-binding protein Hu antigen R (HuR) and degrades 30% HuR at 0.1 μM. HuR degrader 2 inhibits the proliferation of cancer cell Colo-205, with IC50≤200 nM. HuR degrader 2 exhibits a high affinity with cereblon, with an HTRF ratio < 0.02 .
Cat. No.: HY-124648
CAS No.: 1446311-56-3
Purity:  98.85%
Target:  

DNA/RNA Synthesis

Research Areas:  

Inflammation/Immunology

SMN-C2, an analog of RG-7916, is a selective modulator of SMN2 gene splicing that acts by binding SMN2 pre-mRNA, thereby increasing far upstream element binding protein 1 (FUBP1) and KH-spliced RNA binding Protein affinity regulator protein (KHSRP) to the SMN2 pre-mRNA complex. SMN-C2 can be used in spinal muscular atrophy (SMA) research .
Cat. No.: HY-138652
CAS No.: 24593-59-7
Purity:  99.86%
Target:  

Bacterial

Research Areas:  

Others

L-Histidine benzyl ester bistosylate could play a role in the activation of HutP (an RNA-binding protein) .